Highlights on Pancreatic Cancer - aiom.it · d a lla a lla Highlights Pancreatic Cancer...

dalla

alla

Highlights Pancreatic Cancer

Highlights on Pancreatic Cancer

dalla

alla


Dichiarazione potenziali conflitti di interessi

Consulente in advisory board/attività di formazione per:

- Lilly

- Astra Zeneca

- Celgene

- Italfarmaco

- Boehringer Ingelheim

dalla

alla


Agenda

Trattamento neoadiuvante/adiuvante malattia resecabile

Caratterizzazione molecolare nella malattia avanzata

dalla

alla


Agenda


dalla

alla


Cameron JL, Ann Surg 2006

Chirurgia nel rPC

dalla

alla


Chemioterapia adiuvante nel rPC

dalla

alla


Chemioterapia adiuvante nel rPC

Conroy T, N Engl J Med 2018

dalla

alla


Chemioterapia adiuvante

Uesaka, Lancet 2016

dalla

alla


Presented By Cristina Ferrone at 2019 Gastrointestinal Cancer Symposium

dalla

alla


American Intergroup Alliance Definition:

dalla

alla


Terapia neoadiuvante nel rPC (e in parte brPC): studi randomizzati

Golcher, 2015 CTRT -> CH

CH 66 pts

17.4 m

14.4 m 0.96

Casadei, 2015 CTRT -> CH

CH 38 pts

22.4 m

19.5 m 0.973

Jang, 2018 CTRT -> CH -> CT

CH-> CTRT -> CT 57 pts

21 m

12 m 0.028

Preopanc, 2018 CT-> CTRT -> CH -> CT

CH -> CT 244 pts

17.1 m

13.7 m 0.074

PACT-15, 2018

CH -> CT

CH -> CT

CT -> CH -> CT

88 pts

20.4 m

26.4 m

38.2 m

NR

dalla

alla


Reni M, Lancet Gastroenterol Hepatol 2018

Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05)

Presented By Michiaki Unno at 2019 Gastrointestinal Cancer Symposium

Prep-02/JSAP-05 phase II/III study


Study design and statistical analysis


Major Inclusion Criteria


Overall survival in Prep-01 study


Adverse Events in Neoadjuvant Cx

Presented By Andrew Zhu at 2019 Gastrointestinal Cancer Symposium

Operation (resected case)


Pathological findings (resected case)


Overall Survival (ITT)


Forest Plot on Overall Survival


dalla

alla


Agenda



dalla

alla


Genomic profiling in PDAC metastatic setting: <br />what do we know?

Presented By Grainne O'Kane at 2019 Gastrointestinal Cancer Symposium

Promising Outcomes in Targeting HR-DDR in Pancreatic Cancer

Presented By Michael Pishvaian at 2019 Gastrointestinal Cancer Symposium

Patient Demographics


HR-DDR Mutations are not Prognostically Favorable<br />in Platinum-Naïve Pancreatic Adenocarcinoma


HR-DDR Deficiencies Predict OS Improvement<br />in Platinum-Treated Pancreatic Adenocarcinoma


COMPASS study design


COMPASS study: Early results


Overall survival according to modMoffitt and GATA6


Estimated progression free survival according to chemo


Overall survival according to chemotherapy


Genomic profiling


Genomic Profiling: Actionable variants


dalla

alla


Conclusioni

Trattamento neoadiuvante malattia resecabile


dalla

alla


Highlights on Pancreatic Cancer - aiom.it · d a lla a lla Highlights Pancreatic Cancer...

Documents

Transcript of Highlights on Pancreatic Cancer - aiom.it · d a lla a lla Highlights Pancreatic Cancer...